While PTPRT/HCK HSPC murine recipients did not develop overt myeloid leukemia, five out of nine recipients developed splenomegaly with the remaining four recipients demonstrating normal splenic weights (Fig. 3A). This evidence concerns the gene PSMA7 and myeloid leukemia.